Obi Pharma, Inc. · TPEX:4174

Obi Pharma — Shareholder Meeting (June 2025)

28 slides from Obi Pharma's shareholder meeting presentation, June 2025

Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as “believes,” “expects,” “anticipates, ” “ projects,” “ intends,” “should,” “seeks,” “estimates,” “ future ,” “or similar expressions or by discussio
Slide 3: Agenda
Agenda 01 Company Strategy 02 Financial Guidance 03 Looking Forward 3 June 2025
Slide 4: Strategic Pivot: a Renewed Focus & Innovation on ADCs
Strategic Pivot: a Renewed Focus & Innovation on ADCs Termination of Diversify and Focus • Organization Streamlined Globo H Programs on Antibody-Drug • Cost Reduced (OBI-822& OBI-833) Conjugates (ADCs) Products & Platforms • Efficiency Enhanced 4 June 2025
Slide 5: Transform OBI's Operating Model
Transform OBI’s Operating Model Out-license at early stages of clinical development OBI Partners Phase 1 Phase 2 Phase 3 • Focus on safety • Efficacy and safety • Compare experimental to standard treatment • 10-80 patients • 100-300 patients • ~500 to 1000+ patients • ~1 year • Up to 2 years • Sever
Slide 6: OBI is Diversified in Products and Platforms
OBI is Diversified in Products and Platforms Products Business ❖ ADC Assets: Phase 1 Development ❖ OBI-3424: a novel AKR1C3 prodrug in Phase 2 Platforms (Services, Future products, Out-licensing) ❖ OBI’s own-patented ADC Technologies: Sharpened Focuses a key differentiator ❖ Established an “ADC enab
Slide 7: What Can We Do to Prolong Patients' Lives?
What Can We Do to Prolong Patients’ Lives? ✓ ADC Innovation and Evolution ✓ AI-assisted Drug Development ✓ Unlocking next-gen therapies and diagnostics 7 June 2025 Source: WHO Cancer Today; AACR Progress Report 2024
Slide 8: ADCs Experiencing Unprecedented Growth
ADCs Experiencing Unprecedented Growth Rapid expansion projected to continue for the foreseeable future Global ADCs Market Forecast (2014-2030) 60.0 50.0 40.0 31.2% USD Billion 30.0 Global Market CAGR, 2025 Forecast 20.0 2021 Forecast 2019-2030 2018 Forecast CAGR 21.5% 10.0 CAGR 12.7% 0.0 Source 8 J
Slide 9: Precision Medicine: ADCs Deliver Drugs Selectively to Cancer Cells
Precision Medicine: ADCs Deliver Drugs Selectively to Cancer Cells Antibody 7+ Years of ADC Experience Selectively binds to target on cancer cells Payload Drug that kills cancer cells Shielding effect VISION Right Patient Linker Right Drug Connects antibody to payload Right Time 9 June 2025 ADC: Ant
Slide 10: June 2025
ADC recognizes \_ Ne ~ Payload i is rele and the target and \ ~ cancer cell is killed enters the cell ?
Slide 11: ADCs – “Trojan Horses” in the Fight Against Cancer
ADCs – “Trojan Horses” in the Fight Against Cancer A wooden horse is said to have been used by the Greeks during the Trojan War to enter the city of Troy and win the war. ADC Cancer cells 11 June 2025 Source: Liebig Company trade card, public domain
Slide 12: Early Adopter of Next Wave ADCs: Bispecific and Dual-Payload ADCs
Early Adopter of Next Wave ADCs: Bispecific and Dual-Payload ADCs Sophisticated design to overcome tumor heterogeneity and drug resistance Bispecific ADCs and Dual-Payload ADCs Growth Year-on-Year 242 Number of Assets 189 96 70 56 21 32 40 15 16 5 6 10 2 4 6 8 2015 2017 2018 2019 2020 2021 2022 2023
Slide 13: Unlocking the Full Potential of ADCs Across Cancer Types
Unlocking the Full Potential of ADCs Across Cancer Types NEW Bispecific ADC OBI-992 OBI-902 OBI-904 OBI-201 Dual Payload Target TROP2 TROP2 NECTIN-4 HER2 × TROP2 cMET × HER3 Payload Exatecan Exatecan Exatecan Exatecan Undisclosed DAR value 4 4 8 4 - Platform Cysteine Glycan Glycan Current Phase 1 /
Slide 14: Spotlight on a Novel Linker with New Modalities
Spotlight on a Novel Linker with New Modalities Bispecific & HYPrOBI Linker Dual-Payload ADCs 14 June 2025
Slide 15: Linker Masks and Shields Payload to Enhance Antitumor Activity
Linker Masks and Shields Payload to Enhance Antitumor Activity V e h ic le O B I- 9 0 2 1 0 m g /k g D a to - D X d 1 0 m g /k g Colorectal Cancer CDXS G 1 0 m g /k g s a c -T M T 1 0 m g /k g 1500 SG 1250 Vehicle Vehicle T u m o r v o lu m e ( m m ) sac-TMT HA approved 3 1000 Dato-DXd TROP2 ADCs 75
Slide 16: Novel BsADC targeting c-MET x HER3
Novel BsADC targeting c-MET x HER3 Precisely target tumors & Overcome resistance ✓ Address cancer heterogeneity TKI Antibody ✓ Enhance antitumor activity ✓ Potential for reduced toxicity Resistance ✓ Overcome resistance mechanisms ✓ Enhance cancer specificity Activate EGFR cMET HER3 16 June 2025
Slide 17: Exhibits Promising Antitumor Activities
Exhibits Promising Antitumor Activities Innovation Leads to a New Era of Precision Therapies Colorectal Cancer CDX 1750 1750 1500 HER3-DXd1 5 0 0 T u m o r v o lu m e ( m m ) EmrelisTM 3 T u m o r v o lu m e (m m ) 3 1250 1250 EmrelisTM + HER3-DXd 1000 1000 750 750 500 500 c 250 250 cMET 0 x HER3 cM
Slide 18: OBI-201, BsADC Targeting HER2 and TROP2, Overcomes Multidrug Resistance
OBI-201, BsADC Targeting HER2 and TROP2, Overcomes Multidrug-Resistant with HER2 Low PDX Breast Cancer Model Breast Cancer PDX 2500 2500 2250 Enhertu 2250 2000 Vehicle (HER2) T u m o r v o lu m e (m m ) 2000 3 T u m o r v o lu m e (m m ) 1750 Datroway 3 1750 1500 1500 (TROP2) 1250 1250 1000 OBI-20
Slide 19: Platform: Proven Manufacturing Capabilities
Platform: Proven Manufacturing Capabilities Comprehensive Manufacturing from Process to Formulation Process Development • Consistent quality and yield: from 1 gram up to clinical scale Scale and Capability • GMP Drug Substance (DS) 300-400g (recovery over 85%) • Pharmaceutical grade of highly pure A
Slide 20: Multi-platform Next-generation ADC Technologies
Multi-platform Next-generation ADC Technologies ADCs: the ultimate designer drugs to bring better treatment options to patients Obrion Engine ▪ MsADC & BsADC ▪ Dual-payload ADC ▪ DAC ▪ AOC Glycan site-specific platform Novel linker technology powered by Glycan site-specific Next generation dual-payl
Slide 21: Licensing continues to be the key driver for ADC development
Licensing continues to be the key driver for ADC development Notable ADC Deals between big pharma and biotech: 2023- 1H2025 *Potential total deal value ADC Asset • 2023 • 2023 • 2023 • 2024 • 2025 • Licensor: Duality Biologics • Licensor: Daiichi Sankyo • Licensor: SystImmune • Licensor: MediLink •
Slide 22: Multi-billion Merger and Acquisition from 2020 to 2024
Multi-billion Merger and Acquisition from 2020 to 2024 Testament of Big pharma’s deep commitment in ADC development M&A • Seller: Seagen • Seller: Ambrx • Mar 2023 • Jan 2024 • USD 43bn • USD 2bn • Seller: Immunomedics • Sep 2020 • USD 21bn • Seller: ImmunoGen • Seller: Profound Bio • Dec 2023 • Apr
Slide 23: Partnership Models
Partnership Models Innovative Products and Enabling Technologies OBI Pipeline Assets Out-License OBI-992, OBI 902 – Novel TROP2 ADCs License OBI-904 – Novel Nectin-4 ADCs Agreement Bispecific, Dual-Payload ADCs – TROP2 x HER2, c-MET x HER3 Enabling Technologies Out-License (product candidates) Licen
Slide 24: Our Global Partners
Our Global Partners Other Potential Collaborations 24 June 2025 Image generated by Microsoft Copilot
Slide 25: Secure Financial Health, Maximize Shareholders' Value
Secure Financial Health, Maximize Shareholders’ Value Potential BD deals Non-operating Fundraising (5 ADC Products & (Sale of equity 5 Platform Technologies) investments and other assets) Execute cost-cutting measures Increase efficiency 25 June 2025
Slide 26: Experienced Leaders in Drug Development
Experienced Leaders in Drug Development Executive Team Heidi Wang, PhD Ya-Chi Chen, PharmD Kevin Poulos Chief Executive Officer Chief Scientific Officer Chief Business Officer Dong Xu, PhD Colin Kao, CPA Chief Medical Officer Chief Operating Officer SVP, Biostatistics & Data Management Scientific Ad
Slide 27: Old OBI New OBI
Old OBI New OBI ▪ 1st-in-class Bispecific x Dual Payload ADC ▪ Next generation technologies ▪ Innovative linker Globo H Programs ADC Products and Platform Technologies • Phase 3 Study • Out-license at early stages of clinical development • Resource intensive • Maximize and flexible use of resources
Slide 28: Thank You
Thank You Innovation in Action www.obipharma.com 28 June 2025

OBI Pharma — Shareholder Meeting (June 2025) on 6ix

Obi Pharma — Shareholder Meeting (June 2025)

Slide 1: OBI Pharma: Innovation in Action

Slide 2: Safe Harbor Statement

Slide 3: Agenda

Slide 4: Strategic Pivot: a Renewed Focus & Innovation on ADCs

Slide 5: Transform OBI's Operating Model

Slide 6: OBI is Diversified in Products and Platforms

Slide 7: What Can We Do to Prolong Patients' Lives?

Slide 8: ADCs Experiencing Unprecedented Growth

Slide 9: Precision Medicine: ADCs Deliver Drugs Selectively to Cancer Cells

Slide 10: June 2025

Slide 11: ADCs – “Trojan Horses” in the Fight Against Cancer

Slide 12: Early Adopter of Next Wave ADCs: Bispecific and Dual-Payload ADCs

Slide 13: Unlocking the Full Potential of ADCs Across Cancer Types

Slide 14: Spotlight on a Novel Linker with New Modalities

Slide 15: Linker Masks and Shields Payload to Enhance Antitumor Activity

Slide 16: Novel BsADC targeting c-MET x HER3

Slide 17: Exhibits Promising Antitumor Activities

Slide 18: OBI-201, BsADC Targeting HER2 and TROP2, Overcomes Multidrug Resistance

Slide 19: Platform: Proven Manufacturing Capabilities

Slide 20: Multi-platform Next-generation ADC Technologies

Slide 21: Licensing continues to be the key driver for ADC development

Slide 22: Multi-billion Merger and Acquisition from 2020 to 2024

Slide 23: Partnership Models

Slide 24: Our Global Partners

Slide 25: Secure Financial Health, Maximize Shareholders' Value

Slide 26: Experienced Leaders in Drug Development

Slide 27: Old OBI New OBI

Slide 28: Thank You